Excerpt:
The ADA filed a lawsuit on January 31, 2006 against the Alaska Native Tribal Health Consortium and its dental health aide therapists (DHATs) who fill a void left by dentistry's refusal to treat low-income individuals or work in rural areas of Alaska. [4]. The ADA lost that lawsuit and Alaskans' dental health is improving [5]
After the Fluoride Action Network (FAN), which opposes water fluoridation, established its website at fluoridealert.org, the ADA bought the website URL fluoridealert.com, presumably to confuse people seeking the FAN website.
I'm sure it will be reported at the “fluoridealert.com” website. ... The website that gives details of the conference is “fluoridealert.com”. ...
editor.nourishedmagazine.com.au/articles/round-1-is-los... editor.nourishedmagazine.com.au/articles/round-1-is-lost-queenslanders-against-water-flouridation-continue-the-fight
Fluoride Action Network is an international coalition seeking to broaden public awareness about the toxicity of fluoride compounds and the health impacts of ... http://en.wikipedia.org/wiki/Fluoride Excerpt: Fluoride is the anion F−, the reduced form of fluorine when as an ion and when bonded to another element. Both organofluorine compounds and inorganic fluorine containing compounds are called fluorides.[1] Fluoride, like other halides, is a monovalent ion (−1 charge). Its compounds often have properties that are distinct relative to other halides. Structurally, and to some extent chemically, the fluoride ion resembles the hydroxide ion. Fluorine-containing compounds range from potent toxins such as sarin to life-saving pharmaceuticals such as efavirenz, and from inert materials such as calcium fluoride to the highly reactive sulfur tetrafluoride. The range of fluorine-containing compounds is vast because fluorine is capable of forming compounds with all the elements except helium and neon.[2][3] Compounds containing fluoride anions and in many cases those containing covalent bonds to fluorine are called fluorides. http://findarticles.com/p/articles/mi_m1590/is_14_55/ai_55183119/ Excerpt: In March 1995, thousands of Tokyo subway commuters collapsed and 12 died when a Japanese cult dispersed sarin gas, a toxic chemical, in a subway station. Though police quickly arrested more than 200 cult members, the subway terror was a wake-up call to governments around the world. http://flimsysanity.blogspot.com/2007/08/risperdal-approved-for-children.html Excerpt: Thorazine and Haldol were first introduced, psychiatrists themselves said that these neuroleptic drugs were virtually indistinguishable from a "chemical lobotomy." http://www.sntp.net/drugs/thorazine.htm Excerpt: In 1954, Canada's Heinz Lehmann described the "emotional indifference" and specifically called it the "aim" of the treatment. Like Deniker and Delay, he found "the patients under treatment display a lack of spontaneous interest in the environment. . .". Contrary to today's psychiatric PR, the early pioneers plainly stated there was no positive cure or reduction of the patient's delusional symptoms or hallucinatory phenomena. With stronger dosages, there is a marked dulling and blunting of the patient's overall awareness, motor control and "thereness". A 1950 textbook candidly reported the "lobotomylike" impact of Thorazine, and in 1958, Noyes and Kolb summarized in Modern Clinical Psychiatry: "If the patient responds well to the drug, he develops and attitude of indifference both to his surroundings and to his symptoms".The common factor is that the drug strongly reduces awareness and interest with the result the patient doesn't lose their symptoms, they lose interest in them. http://scienceblogs.com/neurophilosophy/2007/08/fda_approves_chemical_lobotomy.php (When I was working at META Svcs. Value Options doctor prescribed Risperdal for me...... I didn't take it long and decided then and there that there was definitely something wrong with the 'WACKO' system, I wonder if they wanted to silence me?) ...cal Excerpt: FDA approves chemical lobotomy for kidsReuters reports that the Food and Drug Administration (FDA) has just approved the use of the antipsychotic drug Risperdal to treat schizophrenia and bipolar disorder in children and teenagers. http://www.sourcewatch.org/index.php?title=Johnson_%26_Johnson Excerpt: Johnson & Johnson is a New Jersey based diversified, global pharmaceutical, health care product and consumer product company. It manufactures a variety of prescription medications and health care products as well as over-the-counter drugs, personal care products and food additives. J&J operates 250 companies in 60 countries. It manufactures drugs for conditions which include neurological, blood and autoimmune diseases as well as pain medications. Top sellers include Risperdal for schizophrenia and Remicade for psoriasis. The company's medical devices and diagnostics division manufactures surgical equipment, monitoring devices, orthopedic products and contact lenses, among its products. Its consumer division includes over-the-counter drugs and products for babies, skin and oral care as well as first aid and women's health.[1] Centocor is a pharmaceutical and biotechnology subsidiary of J&J based in Horsham, Pennsylvania. McNeil Laboratories is a pharmaceutical subsidiary of J&J based in Ft. Washington, PA, just outside of Philadelphia. In the fiscal year ending in December of 2009, the company reported sales of approximately $61.9 billion dollars and had 115,500 employees. [2] http://www.lakelandtimes.com/main.asp?SectionID=9&SubSectionID=9&ArticleID=9484 Excerpt: In 2005, FDA whistleblower Dr. David Graham estimated that off-label use of atypicals could cause as many as 62,000 excess deaths a year. That's 170 deaths a day, and Rhinelander resident Lisa MaKarrall firmly believes that on June 19, 2008, her father, Bruce Bowman, became one of those casualties. Cause of death? The story starts about seven months earlier, in the early fall of 2007, when Bowman fell at home and was admitted to Taylor Park Nursing Home in Rhinelander for rehabilitation. The stay was short, though, and he returned home, only to fall again in early November of that year. That landed him back in Taylor Park on Nov. 5, 2007, where he fell once more three days after arriving. Even though those falls had occurred, and he had suffered a seizure in October, no one attending Bowman upon his admission to Taylor Park thought he had any potentially fatal condition. In assessments given Nov. 8, 2007, Dec. 15, 2007, Jan. 7, 2008, Jan. 29, 2008, Feb. 20, 2008, April 24, 2008, May 11, 2008, and May 15, 2008, assessors answered 'no' to the question: Does the patient have an end-stage disease with six or fewer months to live? Yet, five weeks to the day after the May 15, 2008, assessment, Bowman was dead. How did it happen? What killed him? To the doctor signing the death certificate, Dr. John Frost, it was Marchiafava-Bignami, a rare disease associated with chronic alcoholism. But only several hundred cases have ever been diagnosed worldwide, and MaKarrall says her father wasn't an alcoholic and hadn't even had a beer in 10 years. Bowman's records show conflicting reports about past known alcohol use, but even if he had the syndrome, it is certainly debatable whether that was the immediate cause of death. Bowman was in fact being treated with thiamine, a therapy that, with vitamin B-12, has proven to be effective in boosting recovery in those diagnosed with the syndrome. http://current.com/green/88795960_pbs-dr-david-graham-shows-how-fda-managers-tried-to-silence-him-for-indicating-vioxx-unsafe.htm Excerpt: In his November 2004 testimony before Congress, Dr. Graham suggested that the FDA is reluctant to admit that there are problems with drugs it has already approved. The FDA responded to Dr. Graham's testimony with a public rebuttal. In December 2004, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA) echoed some of Graham's criticism, publishing a series of papers which question the relationship of drug companies to the approval process. According to THE ECONOMIST, the makers of some of the drugs mentioned by Dr. Graham are feeling a financial effect. AstraZeneca's share price fell by 10%. Shares in GlaxoSmithKline fell by 6%. And as for Merck, the maker of Vioxx, traders have made a $40 billion reduction in the company's value. (Read Dr. Graham's testimony and the JAMA articles.) |
Excerpt:
David J. Acer (November 11, 1949 – September 3, 1990) was an American dentist in Florida who was reported to have infected five of his patients, including Kimberly Bergalis, with HIV.[1][2][3]
Acer tested positive for HIV in late 1986 and was diagnosed with AIDS in September 1987, three months prior to performing an invasive dental procedure on Bergalis. Acer closed his practice due to his illness in July 1989, several months before Bergalis was diagnosed with AIDS and he began to be suspected as the source of the virus.[4][5] The Centers for Disease Control and Prevention (CDC) concluded that the patients had contracted the same strain of HIV from Acer. By tests of DNA, the CDC found a high correlation between the strain of HIV carried by Acer and that carried by Bergalis and Acer's other patients. However, the CDC tests were later questioned by the investigative television show 60 minutes and by some medical publications, with one article in the Annals of Internal Medicine stating, "that the molecular analyses used to determine that the dentist and his patients had the same strains of HIV had potentially serious flaws."[2][3][4][5][6]
http://www.nytimes.com/keyword/david-acer
Excerpt:
A retired schoolteacher whom medical experts believe was infected with the virus that causes AIDS by a dentist died on Saturday, said a spokeswoman for the hospice where she died. The teacher, Barbara Webb, 68, was the fourth patient of the dentist, Dr. David Acer, to die of AIDS complications. The first, Kimberly Bergalis, who died in 1991 at the age of 23, became an outspoken advocate of AIDS testing for medical personnel. Ms. Webb had joined Ms. Bergalis in calling for testing of health care workers.
December 19, 1994
http://en.wikipedia.org/wiki/Kimberly_Bergalis
Excerpt:
In addition, the 60 Minutes anchors argued that the CDC may have botched the genetic tests that proved that Bergalis had the same strain of HIV as her dentist. The television broadcast was dismissed by CDC scientists as misleading and inaccurate.[14] Stephen Barr, a journalist who contributed to the show, rebutted this dismissal.[15][16]
http://tmh.floonet.net/articles/poisoned.shtml
Excerpt:
Apart from HIV being a harmless virus, the evidence that this virus has ever been medically transmitted remains dubious. Based on their own research, insurance companies concluded that the HIV strains in the five patients were different from that in Acer, meaning each caught it from a different source.116 A study out of Florida State University has backed this conclusion.117 Even the CDC acknowledged this evidence, though it still preferred to believe the dentist had infected Bergalis.
http://www.sourcewatch.org/index.php?title=GlaxoSmithKline
Excerpt:
GlaxoSmithKline (GSK) is an international pharmaceutical giant headquartered in Britain. GSK traces its heritage back to a London pharmacy established in 1715. Various entities, including Burroughs Wellcome & Company, Smith-Kline & French Laboratories and Glaxo Laboratories merged to form GSK
http://en.wikipedia.org/wiki/GlaxoSmithKline
Exce
GlaxoWellcome
In 1880, Burroughs Wellcome & Company was founded in London by American pharmacists Henry Wellcome and Silas Burroughs.[5] The Wellcome Tropical Research Laboratories opened in 1902.[5] In 1959 the Wellcome Company bought Cooper, McDougall & Robertson Inc. to become more active in animal health.[5] The Wellcome Company production centre was moved from New York to North Carolina in 1970 and the following year another research centre was built.
(AZT)
http://www.gracesguide.co.uk/wiki/Burroughs,_Wellcome_and_Co
http://www.carlyle.com/Media%20Room/News%20Archive/2010/item10891.html
Excerpt:
Hamilton, Bermuda – The Bank of N.T. Butterfield & Son Limited (“Butterfield” or the “Bank”) announced today that funds affiliated with The Carlyle Group (“Carlyle”), Canadian Imperial Bank of Commerce (“CIBC”) and other institutional investors have invested $550 million in new Butterfield equity. Other investors include the Wellcome Trust, The Bermuda Government Pension Funds, Julian Robertson, and Goshen Investments, LLC. As part of the transaction, existing Butterfield shareholders will have the right to participate in a rights offering, proceeds of which will be used to buy back some of the newly issued shares.
http://www.cscr.cam.ac.uk/
Excerpt:
Stained epidermal stem cells, Julien Gautrot, March 2011
The first Cambridge Stem Cell international symposium will be held this summer. Bringing together established leaders and emerging talents in the field to provide an overarching view of pluripotency from a developmental context: how it is established, and how it can be controlled.
No comments:
Post a Comment